At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 2, 2026 at 09:02 ET
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. This is a routine organizational change with no material financial impact.
- Stephen Glover appointed as independent director, granted option to purchase 96,000 shares vesting over 3 years.
- John McAdory promoted to COO, previously EVP of Strategy and Operations; no additional compensation.
- Glover brings public company board and M&A experience, including chairing Ambrx during its $2B acquisition by J&J.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access